chemotherapy-induced side effects.
Conditions
Interventions
Intervention 1: Intervention group: Patients will be given two capsules of lactocare synbiotic daily for 6 weeks. Lactocare Synbiotic Capsules are manufactured by Zist Takhmir Company .Lactocare is an
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Definitive diagnosis of breast cancer by oncologist and pathologist Receiving one-day chemotherapy courses Stage 1 to 3 of breast cancer (pre-metastatic stages) History of complications following previous chemotherapy sessions no history of gastrointestinal problems before breast cancer at least one and at last two previous sessions of chemotherapy Do not consuming probiotic dairy products or any foods containing probiotic or prebiotic compounds, or their supplements in the past two weeks. Age 18 years and older Willingness to cooperation
Exclusion criteria
Exclusion criteria: Chronic diseases such as hypertension, coronary heart disease, history of stroke, liver failure (ALT and AST levels > 100 IU / L), renal failure (serum creatinine levels > 1.7 mg / dl), impaired cell count (WBC > 20,000 U / L, hemoglobin less than 10 mg / dl, platelets 400,000 / mcL) and gastrointestinal problems Body mass index >30 kg / m2 History of tumor in other organs or metastasis to other organs taking medicines or other treatments to reduce nausea (Except for the usual anti-nausea and vomiting medicines) Severe gastrointestinal problems and complications during the study Neutropenic patients Consumption of probiotic dairy products or any foods containing probiotic or prebiotic compounds, or their supplements during the study Recent infection or recent use of antibiotics in the past three months Receiving radiation therapy and chemotherapy simultaneously Not willing to continue cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Experience and severity of nausea. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: McGill Nausea and Vomiting Questionnaire.;Experience and severity of vomiting. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: McGill Nausea and Vomiting Questionnaire.;Experience and severity of diarrhea. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: Bristol Diarrhea and Constipation Scale.;Experience and severity of constipation. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: Bristol Diarrhea and Constipation Scale.;Experience and severity of fatigue. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: CFS questionnaire.;Experience and severity of chemotherapy-induced pain. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: McGill Pain Questionnaire.;Sleep quality. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: PSQL questionnaire.;Experience and severity of anorexia. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: FAACT questionnaire.;Psycho-emotional status. Timepoint: One hour before receiving chemotherapy drugs in the first, second and third visit. Method of measurement: PHQ-9 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzad SHidfar
Iran University of Medical Sciences
Outcome results
None listed